The drug candidate, FX005, is an intra-articular p38 MAP kinase inhibitor that releases encapsulated medicine to suppress inflammation and pain over time rather than all at once. The drug, which is shot directly into the knee joint, provides prolonged relief and minimizes systemic exposure and side effects. Flexion plans to start a phase 2b study in the first half of 2013.
"We believe these data not only demonstrate the therapeutic potential of FX005, but also validate Flexion's approach to the treatment of osteoarthritis," said Flexion CEO Michael Clayman, MD.
Related Articles on Pain Management:
Endo, Watson to Launch Generic Lidoderm in 2013Game Designed to Help Physicians Fight Opioid Abuse
10 Benchmarking Statistics About ASC Pain Management Revenue